Etoposide is a chemotherapy medication used primarily in the treatment of various cancers, including lung cancer, testicular cancer, and certain types of leukemia. It was developed in the 1960s–1970s and approved for medical use in the 1980s. Its history is marked by its effectiveness as an anti-cancer agent, particularly due to its ability to inhibit DNA replication by targeting the enzyme topoisomerase II.
Etoposide is classified as a topoisomerase inhibitor and is commonly included in combination chemotherapy regimens. Its development and clinical use have involved extensive research into dosing strategies and toxicity management, as it can cause significant side effects such as bone marrow suppression. Over time, treatment protocols have evolved to optimize its therapeutic benefits while minimizing risks through careful monitoring and supportive care.
BRAND NAMES
Vepesid – one of the most widely recognized original brand names
Toposar – another commonly used formulation.
MECHANISM OF ACTION
The mechanism of action of Etoposide involves inhibition of the enzyme Topoisomerase II, which plays a crucial role in DNA replication and repair. Etoposide stabilizes the transient complex formed between topoisomerase II and DNA after the enzyme induces double-strand breaks, preventing the re-ligation (resealing) of these breaks.
PHARMACOKINETICS
Absorption
Etoposide can be administered both orally and intravenously. After oral administration, its absorption is variable and incomplete, with an average bioavailability of about 50% (range ~25–75%), meaning only part of the dose reaches systemic circulation.
Distribution
Etoposide has a moderate volume of distribution, typically ranging from 7 to 17 L/m². This indicates that the drug distributes beyond the bloodstream into body tissues but is not extensively taken up into deep compartments.
Metabolism
Etoposide is partially metabolized in the liver, primarily by the Cytochrome P450 enzyme system, especially CYP3A4. It undergoes oxidation and O-demethylation to form both active and inactive metabolites.
Elimination
Etoposide is eliminated through a combination of renal and non-renal pathways. Approximately 40–60% of the administered dose is excreted unchanged in the urine, making the kidneys the primary route of elimination.
PHARMACODYNAMICS
Etoposide exhibits cytotoxic (cell-killing) activity by interfering with DNA processes in rapidly dividing cells. Its primary pharmacodynamic effect is mediated through inhibition of Topoisomerase II, leading to the accumulation of DNA strand breaks and subsequent induction of apoptosis.
ADMINISTRATION
Etoposide can be administered either intravenously (IV) or orally (capsules), depending on the clinical setting and treatment regimen. IV administration is typically given as a slow infusion over 30–60 minutes to minimize the risk of hypotension and allows precise control of drug levels in the blood, making it suitable for hospital or clinic use.
DOSAGE AND STRENGTH
The dosage and strength of Etoposide vary depending on the type of cancer, treatment protocol, and patient-specific factors such as renal or hepatic function. For intravenous administration, the typical dose ranges from 50 to 100 mg/m² per day for 3–5 consecutive days, with some regimens using weekly or biweekly schedules as part of combination therapy.
DRUG INTERACTIONS
Etoposide has several important drug interactions, primarily due to its metabolism by CYP3A4 and its potential to cause bone marrow suppression. Concomitant use with CYP3A4 inhibitors such as ketoconazole or ritonavir can increase etoposide plasma levels, raising the risk of toxicity, while CYP3A4 inducers like rifampin or phenytoin may decrease its effectiveness.
FOOD INTERACTIONS
Oral etoposide can be taken with or without food, but food may slightly delay absorption. The overall extent of absorption (bioavailability) is generally not significantly affected, so dosing adjustments are usually unnecessary.
CONTRAINDICATIONS
Etoposide is contraindicated in patients with a known hypersensitivity to the drug or any of its components, as well as in individuals with severe myelosuppression characterized by critically low white blood cell or platelet counts.
SIDE EFFECTS
Gastrointestinal:
Nausea and vomiting
Diarrhea
Stomatitis
OVER DOSAGE
An overdose of Etoposide can result in severe and potentially life-threatening toxicities, primarily due to profound bone marrow suppression, which may lead to extreme neutropenia, anemia, and thrombocytopenia, increasing the risk of serious infections and bleeding.
TOXICITY
Etoposide exhibits toxicity primarily due to its effects on rapidly dividing cells, with hematologic toxicity being the most significant. It commonly causes myelosuppression, leading to neutropenia, anemia, and thrombocytopenia, which increase the risk of infections, bleeding, and fatigue.
